About NUVESSA
a In a clinical study, NUVESSA demonstrated statistically significantly higher cure rates of a Control Gel.
NUVESSA (metronidazole vaginal gel 1.3%) is the one and only single-dose metronidazole vaginal gel (MVG) indicated to treat bacterial vaginosis in females 12 years of age and older. Its concentrated 1.3% formulation delivers a complete course of therapy in one prefilled applicator, administered at bedtime.1
In a clinical study, one dose of NUVESSA demonstrated comparable efficacy, safety, and tolerability to a 5-day regimen of metronidazole vaginal gel 0.75%.2 For patients who may find multiday treatment challenging, NUVESSA offers a proven, convenient option—with just one dose to remember.
Prescribe NUVESSA and deliver the assurance of the gold standard metronidazole in one targeted dose at bedtime.
Not all metronidazole-containing prescription products are the same3:
| NUVESSA1(Alembic Therapeutics, LLC) | METROGEL-VAGINAL®5(Galderma Holding S.A.) | FLAGYL®6(Wyeth Holdings LLC.) | |
|---|---|---|---|
| Length of Treatment |
1 day | 5 days5 | 7 days |
| Dosage Form | 1 Prefilled Applicator | Medicated gel + unfilled applicator(s) | Oral tablets |
| Duration of Alcohol Restriction |
24 hours1 | 5 days5 | 10 days6 |
When used as directed, a single bedtime dose of NUVESSA avoids adherence issues associated with multi-dose treatments.3
Deliver efficacy with single-dose adherence
- Pre-filled applicator for her convenience1
- Lower systemic exposure (intravaginal administration results in 2-4% of the systemic exposure a single, oral dose of metronidazole 500-mg oral tablets).1
Why prescribe 5 doses when you can prescribe 1?
A 1-time dose at bedtime has been proven effective against bacterial vaginosis (BV)2
In a phase 2, randomized, controlled, investigator-blinded, dose-ranging study, women with BV (N=255) were treated with different metronidazole-based regimens. The primary endpoint was therapeutic cure (defined as clinical plus bacteriologic cure) at Day 21. A 1-time dose of MVG 1.3% at bedtime was equal in terms of safety, efficacy, and tolerability (see chart below).
NUVESSA Outcomes in Comparative and Placebo-Controlled Clinical Trials
b Comparative statistics were not performed.
The primary endpoint in this phase 2 study was therapeutic cure (defined as clinical plus bacteriologic cure) at Day 21. Cure rates at test of cure/end of study: per-protocol2
In a phase 3, double-blind, vehicle-controlled clinical trial, the safety and efficacy of NUVESSA was evaluated in 577 subjects with a clinical diagnosis of BV. The primary endpoint was clinical cure at Day 21, defined as return of physiologic vaginal discharge, confirmed by the investigator with a negative whiff test and clue cells < 20% (with no pH criterion). Results are based on the modified intent-to-treat population.7
c Bacterial vaginosis treatment in a randomized, double-blind, vehicle-controlled, parallel group study (N=577)
d Cure rate difference vs placebo.
Therapeutic cure: Resolution of both clinical signs and bacteriological markers of infection following treatment.
Clinical cure: Return to normal vaginal discharge, negative whiff test, and less than 20% clue cells on saline wet mount, as assessed by the investigator.
Bacteriological cure: Restoration of normal vaginal flora, defined as a Nugent score below 4.1,7
Cure rates at test of cure/end of study: per-protocol1
- At day 7, Clinical Cure was achieved by a statistically significantly greater proportion of patients in the NUVESSA group vs. the vehicle gel group (41.1% vs. 20.0%). Bacteriological Cure was also achieved by a statistically significantly greater proportion of NUVESSA-treated patients vs. the Vehicle Gel group (33.9% vs. 6.3%).1
- The safety of NUVESSA was evaluated in a randomized, double-blind, vehicle-controlled study in subjects with bacterial vaginosis. There were no deaths of serious adverse reactions. Adverse reactions were reported by 19.0% of NUVESSA-treated subjects vs 16.1% of Vehicle Gel-treated subjects.1,e
- Adverse reactions occurring in >1% of subjects receiving NUVESSA were: vulvovaginal candidiasis (5.6%), headache (2.2%), vulvovaginal pruritus (1.6%), nausea (1.6%), diarrhea (1.2%), and dysmenorrhea (1.2%). No subjects discontinued treatment due to adverse reactions.1
e 321 non-pregnant females with a mean age of 33.4 years (range 18-67 years) received NUVESSA. Subjects administered a single dose of NUVESSA at bedtime on the first day of the study.
Why prescribe NUVESSA? It’s convenient for your patients.
- Achieving good patient compliance with multiday regimens can be challenging.3
- Single-dose BV treatments may provide an option for patients who desire greater convenience than multidose regimens.8
| Treatment Protocol | ||||
|---|---|---|---|---|
| Patient Rating of Convenience | 1.3% once daily/1 day (n=43) |
1.3% once daily/3 days (n=48) |
1.3% once daily/5 days (n=49) |
0.75% once daily/5 days (n=49) |
| Very convenient | 81.4%2 | 45.8%2 | 32.7%2 | 34.7%2 |
f A phase 2, randomized, controlled, investigator-blinded, dose-ranging study evaluated women with BV (N=255) who were being treated with different metronidazole-based regimens. The primary endpoint was therapeutic cure (defined as clinical plus bacteriologic cure) at Day 21. There were multiple secondary efficacy measures, including a patient end-of-study questionnaire on treatment satisfaction.3
Is medication adherence a challenge for your patients with bacterial vaginosis (BV)?
- Patient adherence rates to a multi-day metronidazole regimen are as low as 50%2
- Over half of women contracting BV may have recurrence within one year9,10
- Duration of therapy is a potential barrier to adherence for BV treatments8
Percentage of women experiencing repeat BV episodes within 1 year9,10,g
g Recurrence defined as Nugent score 7–10 after treatment with oral metronidazole 400 mg twice daily for 7 days. Study follow-up included 1, 3, 6, and 12 months.10
Explore the Evidence
These materials provide additional information on bacterial vaginosis (BV) diagnosis and management, treatment adherence, and the clinical evidence supporting single-dose NUVESSA. Click on the titles to visit each article, abstract, or resource.
Download these Resources for HCPs
BV Diagnosis and Management
- American College of Obstetricians and Gynecologists. Vaginitis in nonpregnant patients: ACOG Practice Bulletin, Number 215. Obstet Gynecol. 2020;135(1):e1-e17.
- Muzny CA, Kardas P. A narrative review of current challenges in the diagnosis and management of bacterial vaginosis. Sex Transm Dis. 2020;47(7):441-446.
- Sherrard J, et al. 2018 European (IUSTI/WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258-1272.
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187.
Treatment Adherence and BV Recurrence
- Bartley JB, Ferris DG, Allmond LM, et al. Personal digital assistants used to document compliance of bacterial vaginosis treatment. Sex Transm Dis. 2004;31(8):488-491.
- Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478-1486.
NUVESSA Clinical Evidence
- Chavoustie SE, Jacobs M, Reisman HA, et al. Metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis: a dose-ranging study. J Low Genit Tract Dis. 2015;19(2):129-134.
- Schwebke JR, Marrazzo J, Beelen AP, et al. A phase 3, multicenter, randomized, double-blind, vehicle-controlled study evaluating the safety and efficacy of metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis. Sex Transm Dis. 2015;42(7):376-381.
- Alembic Therapeutics LLC. NUVESSA (metronidazole vaginal gel 1.3%) prescribing information. Bedminster, NJ: Alembic Therapeutics LLC; revised July 2026.
Metronidazole Treatment and Comparative Evidence
- Hirai J, Arakawa Y, Kato H, Takano T, et al. Comparative efficacy and safety of oral versus intravaginal metronidazole for the treatment of bacterial vaginosis: a systematic review and meta-analysis. J Infect Chemother. 2025;31:102826.
- Merative, Micromedex. Metronidazole (oral route): side effects and dosage. Mayo Clinic. Updated June 1, 2026.
- Teva Pharmaceuticals USA. Metronidazole vaginal gel 0.75% prescribing information. Sellersville, PA: Teva Pharmaceuticals USA; 2005.
Resources for Your Patients
Learn more about bacterial vaginosis (BV) and treatment with NUVESSA. Our patient brochure explains BV symptoms, risk factors and testing, what makes single-dose NUVESSA different, and ways eligible patients may save on their prescription.
Understanding BV and NUVESSA
The NUVESSA patient brochure offers helpful information about BV and its treatment with NUVESSA.
Savings Program
Eligible patients may pay as little as $25h for their prescription
h The patient is responsible for the first $25 of their co-pay and cash-paying patients should pay approximately $55. For cash paying patients or insured patients when NUVESSA is not covered by primary insurance, patients may still use this savings card but may have an outstanding balance. Please see Program Terms, Conditions, and Eligibility Criteria on savings card.
Brochure
References: 1. Nuvessa prescribing information. 2. Chavoustie SE, et al. J Low Genit Tract Dis. 2015;19(2):129-134. 3. Bartley JB, et al. Sex Transm Dis. 2004;31(8):488-491. 4. Hirai J, et al. J Infect Chemother. 2025;31(11):102826. 5. Metrogel® prescribing information. 6. Flagyl® prescribing information. 7. Schwebke JR, et al. Sex Transm Dis. 2015;42:376-381. 8. Muzny CA. Sex Transm Dis. 2020;47(7):441-446. 9. Sherrard J, et al. Int J STD AIDS. 2023;34(10):745. 10. Bradshaw CS, et al. J Infect Dis. 2006;193(11):1478-1486.
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION
NUVESSA (metronidazole vaginal gel 1.3%) is an intravaginal treatment indicated for the treatment of bacterial vaginosis in females 12 years of age and older.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
NUVESSA is contraindicated in:
- Patients with a history of hypersensitivity to metronidazole, parabens, other ingredients of the formulation, or other nitroimidazole derivatives.
- Patients using disulfiram or within 2 weeks of disulfiram use.
- Patients using alcohol. Alcoholic preparations (e.g., ethanol, propylene glycol) and beverages should not be consumed during and for at least 24 hours after NUVESSA therapy.
WARNINGS and PRECAUTIONS
Central and Peripheral Nervous System Effects
Convulsive seizures, encephalopathy, aseptic meningitis, optic and peripheral neuropathy have been reported in patients treated with oral or intravenous metronidazole. NUVESSA should be administered with caution to patients with central nervous system diseases.
Discontinue promptly if abnormal neurologic signs development.
Carcinogenicity in Animals
Metronidazole has been shown to be carcinogenic at high doses administered orally in mice and rats. Unnecessary use of metronidazole should be avoided.
Drug/Laboratory Test Interactions
Metronidazole may interfere with certain serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed.
Adverse Reactions
The most common adverse reactions (≥1%) observed in adult clinical studies were vulvovaginal candidiasis, headache, vulvovaginal pruritus, nausea, diarrhea, and dysmenorrhea.
The most common adverse reactions (≥1%) observed in pediatric clinical studies was vulvovaginal discomfort.
This is not a complete list of risks.
Please see full Prescribing Information for detailed information here.